1
|
Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol 2018; 28:1070-1077. [PMID: 28453704 DOI: 10.1093/annonc/mdx048] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Background HER2 (ERBB2) gene amplification and its corresponding overexpression are present in 15-30% of invasive breast cancers. While HER2-targeted agents are effective treatments, resistance remains a major cause of death. The American College of Surgeons Oncology Group Z1041 trial (NCT00513292) was designed to compare the pathologic complete response (pCR) rate of distinct regimens of neoadjuvant chemotherapy and trastuzumab, but ultimately identified no difference. Patients and methods In supplement to tissues from 37 Z1041 cases, 11 similarly treated cases were obtained from a single institution study (NCT00353483). We have extracted genomic DNA from both pre-treatment tumor biopsies and blood of these 48 cases, and performed whole genome (WGS) and exome sequencing. Coincident with these efforts, we have generated RNA-seq profiles from 42 of the tumor biopsies. Among patients in this cohort, 24 (50%) achieved a pCR. Results We have characterized the genomic landscape of HER2-positive breast cancer and investigated associations between genomic features and pCR. Cases assigned to the HER2-enriched subtype by RNA-seq analysis were more likely to achieve a pCR compared to the luminal, basal-like, or normal-like subtypes (19/27 versus 3/15; P = 0.0032). Mutational events led to the generation of putatively active neoantigens, but were overall not associated with pCR. ERBB2 and GRB7 were the genes most commonly observed in fusion events, and genomic copy number analysis of the ERBB2 locus indicated that cases with either no observable or low-level ERBB2 amplification were less likely to achieve a pCR (7/8 versus 17/40; P = 0.048). Moreover, among cases that achieved a pCR, tumors consistently expressed immune signatures that may contribute to therapeutic response. Conclusion The identification of these features suggests that it may be possible to predict, at the time of diagnosis, those HER2-positive breast cancer patients who will not respond to treatment with chemotherapy and trastuzumab. ClinicalTrials.gov identifiers NCT00513292, NCT00353483.
Collapse
Affiliation(s)
- R Lesurf
- McDonnell Genome Institute at Washington University School of Medicine, St Louis, USA
| | - O L Griffith
- McDonnell Genome Institute at Washington University School of Medicine, St Louis, USA,Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, USA,Siteman Cancer Center, Washington University School of Medicine, St Louis, USA
| | - M Griffith
- McDonnell Genome Institute at Washington University School of Medicine, St Louis, USA,Siteman Cancer Center, Washington University School of Medicine, St Louis, USA,Department of Genetics, Washington University School of Medicine, St Louis, USA
| | - J Hundal
- McDonnell Genome Institute at Washington University School of Medicine, St Louis, USA
| | - L Trani
- McDonnell Genome Institute at Washington University School of Medicine, St Louis, USA
| | - M A Watson
- Department of Pathology & Immunology, Washington University School of Medicine, St. Louis
| | - R Aft
- Siteman Cancer Center, Washington University School of Medicine, St Louis, USA
| | - M J Ellis
- McDonnell Genome Institute at Washington University School of Medicine, St Louis, USA,Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, USA,Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA
| | - D Ota
- Duke University Medical Center, Durham
| | - V J Suman
- Alliance Statistics and Data Center, Mayo Clinic, Rochester
| | | | - A M Leitch
- The University of Texas Southwestern Medical Center, Dallas
| | | | | | - A U Buzdar
- The University of Texas MD Anderson Cancer Center, Houston
| | - K K Hunt
- The University of Texas MD Anderson Cancer Center, Houston
| | - E R Mardis
- Institute for Genomic Medicine, The Research Institute at Nationwide Children's Hospital, Columbus, USA,Department of Pediatrics, The Ohio State University College of Medicine, Columbus, USA
| |
Collapse
|
2
|
Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat 2016; 161:363-373. [PMID: 27866278 DOI: 10.1007/s10549-016-4051-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Accepted: 11/05/2016] [Indexed: 01/09/2023]
Abstract
PURPOSE We examined acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) events among 9679 women treated for breast cancer on four adjuvant Alliance for Clinical Trials in Oncology trials with >90 months of follow-up in order to better characterize the risk for AML/MDS in older patients receiving anthracyclines. METHODS We used multivariable Cox regression to examine factors associated with AML/MDS, adjusting for age (≥65 vs. <65 years; separately for ≥70 vs. <70 years), race/ethnicity, insurance, performance status, and anthracycline receipt. We also examined the effect of cyclophosphamide, the interaction of anthracycline and age, and outcomes for those developing AML/MDS. RESULTS On Cancer and Leukemia Group B (CALGB) 40101, 49907, 9344, and 9741, 7290 received anthracyclines; 15% were in the age ≥65 and 7% were ≥70. Overall, 47 patients developed AML/MDS (30 AML [0.3%], 17 MDS [0.2%]); 83% of events occurred within 5 years of study registration. Among those age ≥65 and ≥70, 0.8 and 1.0% developed AML/MDS (vs. 0.4% for age <65), respectively. In adjusted analyses, older age and anthracycline receipt were significantly associated with AML/MDS (adjusted hazard ratio [HR] for age ≥65 [vs. <65] = 3.13, 95% confidence interval [CI] 1.18-8.33; HR for anthracycline receipt [vs. no anthracycline] = 5.16, 95% CI 1.47-18.19). There was no interaction between age and anthracycline use. Deaths occurred in 70% of those developing AML/MDS. CONCLUSIONS We observed an increased risk for AML/MDS for older patients and those receiving anthracyclines, though these events were rare. Our results help inform discussions surrounding anticipated toxicities of adjuvant chemotherapy in older patients.
Collapse
Affiliation(s)
- Rachel A Freedman
- Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
| | - D K Seisler
- Alliance Statistics and Data Center, Mayo Clinic and Mayo Cancer Center, Rochester, MN, USA
| | - J C Foster
- Alliance Statistics and Data Center, Mayo Clinic and Mayo Cancer Center, Rochester, MN, USA
| | - J A Sloan
- Alliance Statistics and Data Center, Mayo Clinic and Mayo Cancer Center, Rochester, MN, USA
| | - J M Lafky
- Mayo Clinic College of Medicine, Rochester, MN, USA
| | - G G Kimmick
- Duke University School of Medicine, Durham, NC, USA
| | - A Hurria
- Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, City of Hope, Duarte, CA, USA
| | - H J Cohen
- Duke University School of Medicine, Durham, NC, USA
| | - E P Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
| | - C A Hudis
- Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - A H Partridge
- Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
| | - L A Carey
- Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA
| | - A Jatoi
- Mayo Clinic College of Medicine, Rochester, MN, USA
| | - H D Klepin
- Department of Hematology and Oncology, Wake Forest University, Winston-Salem, NC, USA
| | - M Citron
- ProHEALTH Care Associates, Lake Success, NY, USA
| | - D A Berry
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - L N Shulman
- Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - A U Buzdar
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - V J Suman
- Alliance Statistics and Data Center, Mayo Clinic and Mayo Cancer Center, Rochester, MN, USA
| | - H B Muss
- Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC, USA
| |
Collapse
|
3
|
Lesurf R, Griffith O, Griffith M, Watson MA, Hoog J, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Abstract PD6-02: The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer – Results from the ACOSOG Z1041 (Alliance) trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-pd6-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Support: Alliance U10CA180821; Alliance Statistical Center grant U10CA180882; ACOSOG grant U10CA76001
HER2 gene amplification and its corresponding overexpression are present in approximately 12% of invasive breast cancers. While HER2-targeted agents (e.g. trastuzumab, pertuzumab, and lapatinib) are effective treatments, resistance remains a major cause of death from HER2-positive breast cancer. Mechanisms of resistance are poorly understood. Without a molecular understanding of these mechanisms, therapeutic advances will be delayed. We have generated molecular profiles of primary HER2-positive breast cancers treated on a neoadjuvant clinical trial, and compared features associated with response to treatment.
The American College of Surgeons Oncology Group (ACOSOG) Z1041 trial in HER2-positive breast cancer was designed to compare the pathologic complete response (pCR) rate of a regimen of paclitaxel and trastuzumab, followed by trastuzumab administered with fluorouracil, epirubicin, and cyclophosphamide (FEC-75) to a regimen of FEC-75 alone followed by paclitaxel and trastuzumab. The trial identified no difference in pCR rates between the regimens (Buzdar et al., The Lancet Oncology 2013). In supplement to the tissues obtained from 37 of the patients enrolled in the Z1041 trial, an additional 11 cases were obtained from a single institution study (201101961) of patients treated with neoadjuvant trastuzumab that had pre-treatment core biopsies suitable for genomic studies.
We have extracted genomic DNA from both pretreatment tumor biopsies and blood samples of these 48 patients and performed whole genome (WGS) and exome sequencing. Coincident with these efforts, we have extracted high quality RNA from 42 of the 48 biopsies, and have processed RNA-seq profiles of the tumors. Among patients in this cohort, 24 (50%) achieved a pCR. Because no difference was observed between arms of the Z1041 trial, patients with or without a pCR were directly compared without adjusting for treatment regimen.
On average, each tumor and normal sample pair were sequenced to a depth of 49.4x and 32.5x by WGS respectively. In total, 15,027 candidate somatic variants were identified in known genes, including 11,606 missense, 860 nonsense, and 418 frameshift insertions or deletions. Preliminary results identified mutations in HER2 that were associated with the failure to achieve pCR in several cases. Furthermore, tumors assigned to the HER2-enriched subtype by RNA-seq analysis were more likely to achieve a pCR (19 compared to 8) than tumors with genomic features indicative of either the luminal or basal-like subtypes (3 compared to 12); a significant difference in the proportion of cases that achieve pCR (Fisher's exact test p-value = 0.0032). The identification of these features suggests that it may be possible to predict, at the time of diagnosis, those patients who will not respond to the current standard of care for HER2-positive breast cancer.
Citation Format: Lesurf R, Griffith O, Griffith M, Watson MA, Hoog J, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer – Results from the ACOSOG Z1041 (Alliance) trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD6-02.
Collapse
Affiliation(s)
- R Lesurf
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - O Griffith
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - M Griffith
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - MA Watson
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - J Hoog
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - MJ Ellis
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - D Ota
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - VJ Suman
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - F Meric-Bernstam
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - AM Leitch
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - JC Boughey
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - G Unzeitig
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - AU Buzdar
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - KK Hunt
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| | - ER Mardis
- McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO; Baylor College of Medicine, Houston, TX; Duke University Medical Center, Durham, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Doctors Hospital of Laredo, Laredo, TX
| |
Collapse
|
4
|
Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, Bender M, Shah RR, Hortobagyi GN, Hunt KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol 2014; 25:1004-11. [PMID: 24562447 DOI: 10.1093/annonc/mdu053] [Citation(s) in RCA: 151] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Guidelines for the use of chemotherapy and endocrine therapy recently recommended that estrogen receptor (ER) status be considered positive if ≥1% of tumor cells demonstrate positive nuclear staining by immunohistochemistry. In clinical practice, a range of thresholds are used; a common one is 10% positivity. Data addressing the optimal threshold with regard to the efficacy of endocrine therapy are lacking. In this study, we compared patient, tumor, treatment and survival differences among breast cancer patients using ER-positivity thresholds of 1% and 10%. METHODS The study population consisted of patients with primary breast carcinoma treated at our center from January 1990 to December 2011 and whose records included complete data on ER status. Patients were separated into three groups: ≥10% positive staining for ER (ER-positive ≥10%), 1%-9% positive staining for ER (ER-positive 1%-9%) and <1% positive staining (ER-negative). RESULTS Of 9639 patients included, 80.5% had tumors that were ER-positive ≥10%, 2.6% had tumors that were ER-positive 1%-9% and 16.9% had tumors that were ER-negative. Patients with ER-positive 1%-9% tumors were younger with more advanced disease compared with patients with ER-positive ≥10% tumors. At a median follow-up of 5.1 years, patients with ER-positive 1%-9% tumors had worse survival rates than did patients with ER-positive ≥10% tumors, with and without adjustment for clinical stage and grade. Survival rates did not differ significantly between patients with ER-positive 1%-9% and ER-negative tumors. CONCLUSIONS Patients with tumors that are ER-positive 1%-9% have clinical and pathologic characteristics different from those with tumors that are ER-positive ≥10%. Similar to patients with ER-negative tumors, those with ER-positive 1%-9% disease do not appear to benefit from endocrine therapy; further study of its clinical benefit in this group is warranted. Also, there is a need to better define which patients of this group belong to basal or luminal subtypes.
Collapse
Affiliation(s)
- M Yi
- Department of Surgical Oncology
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 2013; 24:1999-2004. [PMID: 23562929 DOI: 10.1093/annonc/mdt131] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND We sought to determine the prognostic value of pathologic response to neoadjuvant chemotherapy with concurrent trastuzumab. PATIENTS AND METHODS Two hundred and twenty-nine women with HER2/neu (HER2)-overexpressing breast cancer were treated with neoadjuvant chemotherapy plus trastuzumab between 2001 and 2008. Patients were grouped based on pathologic complete response (pCR, n = 114) or less than pCR (<pCR, n = 115); as well as by pathologic stage. Locoregional recurrence-free (LRFS), distant metastasis-free (DMFS), recurrence-free (RFS), and overall survival (OS) rates were compared. RESULTS The median follow-up was 63 (range 53-77) months. There was no difference in clinical stage between patients with pCR or <pCR. Compared with patients achieving <pCR, those with the pCR had higher 5-year rates of LRFS (100% versus 95%, P = 0.011), DMFS (96% versus 80%, P < 0.001), RFS (96% versus 79%, P < 0.001), and OS (95% versus 84%, P = 0.006). Improvements in RFS and OS were seen with decreasing post-treatment stage. Failure to achieve a pCR was the strongest independent predictor of recurrence (hazard ratio [HR] = 4.09, 95% confidence interval [CI]: 1.67-10.04, P = 0.002) and death (HR = 4.15, 95% CI: 1.39-12.38, P = 0.011). CONCLUSIONS pCR and lower pathologic stage after neoadjuvant chemotherapy with trastuzumab are the strongest predictors of recurrence and survival and are surrogates of the long-term outcome in patients with HER2-overexpressing disease.
Collapse
Affiliation(s)
- M M Kim
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Buzdar AU, Xu B, Digumarti R, Goedhals L, Hu X, Semiglazov V, Cheporov S, Gotovkin E, Hoersch S, Rittweger K, Miles DW, O'Shaughnessy J, Tjulandin S. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Ann Oncol 2012; 23:589-597. [PMID: 21633047 DOI: 10.1093/annonc/mdr256] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND This phase II study investigated whether a lower-than-approved dose of capecitabine, plus docetaxel (XT), would improve tolerability versus standard-dose XT without compromising efficacy. PATIENTS AND METHODS Women aged ≥18 years with locally advanced/metastatic breast cancer resistant to anthracycline-based chemotherapy in the (neo)adjuvant, first- or second-line metastatic setting were eligible. Patients were randomly assigned to receive standard-dose XT (capecitabine 1250 mg/m(2) twice daily, days 1-14; docetaxel 75 mg/m(2), day 1 every 3 weeks) or low-dose XT (capecitabine 825 mg/m(2) twice daily, days 1-14; docetaxel as above). The primary objective was to demonstrate non-inferiority of low-dose to standard-dose XT in terms of progression-free survival (PFS). RESULTS 470 patients were randomly allocated in a 1 : 1 ratio to standard-dose or low-dose XT. Median PFS was 7.9 versus 5.8 months [hazard ratio 1.16, 95% confidence interval (CI) 0.95-1.43] in the standard-dose and low-dose arms, respectively. The upper limit of the 95% CI was above the predefined non-inferiority margin (1.35, P = 0.078). Secondary efficacy end points were consistent with PFS. The frequency and severity of adverse events was similar in both treatment arms. CONCLUSIONS Non-inferiority of low-dose to standard-dose XT in terms of PFS was not demonstrated; this may be due to regional subgroup effects.
Collapse
Affiliation(s)
- A U Buzdar
- Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
| | - B Xu
- Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - R Digumarti
- Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, India
| | - L Goedhals
- Department of Oncotherapy, National Hospital, Bloemfontein, South Africa
| | - X Hu
- Cancer Hospital, Fudan University, Shanghai, China
| | - V Semiglazov
- Breast Cancer Department, NN Petrov Research Institute of Oncology, St Petersburg, Russia
| | - S Cheporov
- Department of Oncology, Regional Clinical Oncology Hospital, Yaroslavl, Russia
| | - E Gotovkin
- Department of Oncology, Regional Oncology Dispensary, Ivanovo, Russia
| | - S Hoersch
- Department of Statistics, Dr Manfred Köhler GmbH, Freiburg, Germany
| | - K Rittweger
- Product Development Oncology Department, Hoffmann-La Roche Inc, Nutley, USA
| | - D W Miles
- Department of Medical Oncology, East and North Hertfordshire NHS Trust, Mount Vernon Cancer Centre, Middlesex, UK
| | - J O'Shaughnessy
- Department of Medical Oncology, Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, USA
| | - S Tjulandin
- Department of Clinical Pharmacology and Chemotherapy, Blokhin Cancer Research Center, Moscow, Russia
| |
Collapse
|
7
|
Vachon CM, Brandt KR, Suman VJ, Weinshilboum R, Kosel ML, Wu F, Serie DJ, Olson JE, Buzdar AU, Shepherd LE, Goss PE, Ingle JN. Abstract P2-09-03: Mammographic Density Response to Aromatase Inhibitor Therapy. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-09-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Mammographic density, the variation in fat, epithelial and stromal tissues seen on screening mammography, is a strong risk factor for breast cancer and can be modified by hormonal agents. Changes in density from tamoxifen or postmenopausal hormone (PMH) use are associated with risk, suggesting that density may be a surrogate marker of therapeutic efficacy. Aromatase inhibitors (AIs) are given as adjuvant therapy in hormone receptor positive postmenopausal breast cancer and are known to decrease levels of estrone and estradiol in both serum and breast tissue. Our goal here was to examine the influence of AIs on mammographic density in women with early breast cancer.
Methods: We conducted a case-control study of postmenopausal breast cancer patients initiating adjuvant AI therapy (anastrozole or exemestane) on protocols NCIC CTG MA27, NCCTG N063I and MC (Mayo Clinic) 0532. Eligibility included; an intact contralateral breast with no prior surgery; a screening mammogram within twelve months before AI initiation and at 9-15 months on therapy; no prior endocrine therapy and informed consent. Controls were sampled from the Mayo Mammography Health Study, a cohort of 19,924 receiving screening mammography at the Mayo Clinic, and matched to cases on age, prior PMH use, baseline body mass index (BMI) and interval between mammograms. Pre-treatment and on-study mammograms for cases (corresponding mammograms for controls) were digitized. Change in percent density was estimated on the craniocaudal view of the non-cancerous breast using two methods: a subjective assessment of change by an expert radiologist (within 5%; 5-10% increase, 10-25% increase, 25%+ increase, 5-10% decrease, 10-25% decrease and 25%+ decrease) and a quantitative assessment of absolute change using a computer-assisted thresholding program (Cumulus). Analyses compared magnitude of change in density by both the subjective and quantitative methods between cases and matched controls. Results: 574 pairs were eligible for analyses (MA27-505 cases; N063I-12 cases; MC0532-57 cases). Characteristics of the two groups are shown in the table below. Using either density estimation method, there was a greater decrease in density among women on AI therapy vs. matched controls. In 33% (95% CI: 29-37%) of pairs, there was at least a one greater category decrease for the case relative to her control by subjective estimation. In 14% (95% CI: 11-18%) of the pairs, there was at least a 5% greater decrease for the case relative to her control by quantitative estimation. Data will be available according to AI class (non-steroidal versus steroidal) in November.
Conclusions: In the largest report to date to examine the influence of AI therapy on mammographic density, we provide evidence that AI is associated with decreases in density in a small subgroup of women. We are currently examining factors that influence these AI-associated decreases in density and whether these differences are unique to one class of AI. (Supported in part by NIH grants P50CA116201, U01GM61388, U10CA77202, U10CA25224)
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-03.
Collapse
Affiliation(s)
- CM Vachon
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - KR Brandt
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - VJ Suman
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - R Weinshilboum
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - ML Kosel
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - F Wu
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - DJ Serie
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - JE Olson
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - AU Buzdar
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - LE Shepherd
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - PE Goss
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| | - JN. Ingle
- Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
8
|
Buzdar AU, Green MC, Broglio KR, Carter CD, Valero V, Ibrahim NK, Hunt KK, Hortobagyi GN. Prospective randomized trial evaluating weekly paclitaxel (WP) versus docetaxel in combination with capecitabine (DC) in operable breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.542] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
542 Background: Paclitaxel has scheduled-dependant efficacy, and WP is associated with better therapeutic index (J Clin Oncol. 2005;23:5983–5992). The DC combination had higher response rate, longer control of disease, and improved survival in metastatic disease (J Clin Oncol. 2002;20:2812–2823). This randomized study compared the efficacy and safety of WP to DC in patients (pts) with operable breast cancer. Methods: Pts were randomized 1:1 and stratified by the timing of therapy (preoperative vs adjuvant). The primary endpoint was disease-free survival (DFS), and the secondary endpoint in pts receiving preoperative therapy was complete pathologic response (pCR). WP arm was paclitaxel 80 mg/m2 weekly for 12 weeks, followed by 4 cycles of FEC. DC arm included docetaxel 75 mg/m2 day 1, and capecitabine 1500mg/m2 daily for 14 days of each 3 week cycle for a planned 4 cycles of DC followed by 4 cycles of FEC. The study was designed to include 930 pts to have 80% power to detect a difference in 4 year DFS from 85% on the WP arm to 92% on the DC arm, based on a two-sided test at the 0.05 significance level. Results: 601 pts were randomized, 304 on WP arm and 297 on DC arm. 37% of pts on each arm received therapy in the preoperative setting. Pts characteristics were balanced between the two arms. Median follow-up was 38 months. 4-year DFS on DC arm was 91.0% (95% confidence interval [CI], 84.8- 94.1) and the 4-year DFS on the WP arm was 89.3% (95% CI, 84.8- 94.1) (p = 0.957). A total of 107 pts have been treated with DC and 109 have been treated with WP in the preoperative setting and are evaluable for pCR. The pCR rates were 18.7% and 17.4% on each arm respectively (p = 0.81). The DC arm had higher incidence of hand foot syndrome, and myelosuppression, and WP treatment was associated with higher neurotoxicity. Interim data was presented June 2008 to the institutional data monitoring committee and the study was closed due to futility. If the trial had continued as planned, the predictive probability of concluding in favor of the DC arm for DFS and pCR were 0.005 and 0.001, respectively. Conclusions: WP and DC as utilized in this study had similar efficacy in pts with early stage breast cancer. WP was a better tolerated therapy, associated with little myelotoxicity. [Table: see text]
Collapse
Affiliation(s)
- A. U. Buzdar
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - M. C. Green
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - K. R. Broglio
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - C. D. Carter
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - V. Valero
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - N. K. Ibrahim
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - K. K. Hunt
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
9
|
Mittendorf EA, Tucker SL, Jeruss JS, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a novel staging system for breast cancer patients treated with neoadjuvant chemotherapy. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.558] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
558 Background: We previously described a novel staging system to assess patient prognosis after neoadjuvant chemotherapy based on pretreatment clinical stage (CS), post-treatment pathologic stage (PS), estrogen receptor (E) status and grade (G). This CPS+EG staging system was determined by points assigned for each variable and allowed for better determination of breast cancer specific survival than either CS or PS alone. The current study was undertaken to validate this staging system in a more contemporary cohort of patients. Methods: A prospectively collected database of patients treated with neoadjuvant chemotherapy from 2003 to 2005 identified 804 eligible patients for analysis. Because determination of the CPS+EG staging system predated the use of neoadjuvant trastuzumab therapy, patients receiving neoadjuvant trastuzumab were excluded from the validation cohort. Clinicopathologic characteristics, treatment regimens and patient outcomes were assessed. Patient outcomes were stratified according to their CPS+EG score. Results: Median follow-up time was 3.4 years (range 0.3–5.9 years). The 5-year disease specific survival (DSS) rate for the entire cohort was 77% (95% CI: 72–82). The table summarizes 5-year DSS rates for each CPS+EG score. The pattern of prediction determined in the initial cohort was again seen in the validation cohort. Application of the staging system facilitated separation of patients into more refined subgroups by outcome than the current AJCC staging system applied to either presenting clinical stage or final pathologic stage. Conclusions: This study validates our previously published CPS+EG staging system. We suggest that the AJCC staging system should be revised to incorporate biologic markers and response to treatment for patients receiving neoadjuvant chemotherapy. As targeted agents are being increasingly employed in treatment regimens, future work will focus on further refinement of the staging system with additional biologic markers. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. A. Mittendorf
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Northwestern University, Chicago, IL
| | - S. L. Tucker
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Northwestern University, Chicago, IL
| | - J. S. Jeruss
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Northwestern University, Chicago, IL
| | - A. M. Gonzalez-Angulo
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Northwestern University, Chicago, IL
| | - T. A. Buchholz
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Northwestern University, Chicago, IL
| | - A. A. Sahin
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Northwestern University, Chicago, IL
| | - J. N. Cormier
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Northwestern University, Chicago, IL
| | - A. U. Buzdar
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Northwestern University, Chicago, IL
| | - G. N. Hortobagyi
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Northwestern University, Chicago, IL
| | - K. K. Hunt
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Northwestern University, Chicago, IL
| |
Collapse
|
10
|
Hawke D, Mazouni C, André F, Baggerly K, Baggerly K, Tsavachidis S, Buzdar AU, Martin P, Kobayashi R, Pusztai L. Evaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF/MS procedure. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22072 Evaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF / MS procedure. Background: Response to primary chemotherapy (CT) for breast cancer is heterogeneous among patients and a more tailored treatment would be beneficial in term of reducing exposure to an unnecessary toxicity and optimization of response rates. Mass spectrometry analysis of serum might be helpful in detecting specific changes in response to primary CT. Methods: An applied Biosystems 4700 Proteomics Analyzer matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer was used. A breast cancer cohort of 78 sera samples from 39 HER2 positive patients consisting of matched pretreatment and (6 months) posttreatment samples was used. Blood samples were collected serially before each treatment cycle every 3 weeks of neoadjuvant CT. Samples were divided into those who achieved pathological complete response (pCR, n= 20) and those who had residual disease (RD, n=19). Low-mass differentially expressed peptides were identified using MALDI-TOF/TOF. Results: This procedure yielded a total of 2329 and 3152 peaks respectively, for the responders and non-responders. Biological variation analysis revealed a total of 32 peaks for responders and 643 peaks for non-responders to be differentially regulated with a false discovery rate less than 20%. A total of 8 differentially expressed proteins were identified from their peptides after digestion and LC-MALDI-TOF/TOF. Four in tumors with pCR (AFM, C3, hemopexin, SAP) and four proteins in the RD group were identified (AP1, hemopexin, Complement B, amyloid P component) Conclusions: Our study suggests that MALDI mass spectrometry may be used to predict the tumor response to neoadjuvant chemotherapy. Proteomic analysis may be useful in developing tailored chemotherapy for breast cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Hawke
- UT M. D. Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, villejuif, France; M.D. Anderson Cancer Center, houston, TX; Marseille University, Marseille, France
| | - C. Mazouni
- UT M. D. Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, villejuif, France; M.D. Anderson Cancer Center, houston, TX; Marseille University, Marseille, France
| | - F. André
- UT M. D. Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, villejuif, France; M.D. Anderson Cancer Center, houston, TX; Marseille University, Marseille, France
| | - K. Baggerly
- UT M. D. Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, villejuif, France; M.D. Anderson Cancer Center, houston, TX; Marseille University, Marseille, France
| | - K. Baggerly
- UT M. D. Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, villejuif, France; M.D. Anderson Cancer Center, houston, TX; Marseille University, Marseille, France
| | - S. Tsavachidis
- UT M. D. Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, villejuif, France; M.D. Anderson Cancer Center, houston, TX; Marseille University, Marseille, France
| | - A. U. Buzdar
- UT M. D. Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, villejuif, France; M.D. Anderson Cancer Center, houston, TX; Marseille University, Marseille, France
| | - P. Martin
- UT M. D. Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, villejuif, France; M.D. Anderson Cancer Center, houston, TX; Marseille University, Marseille, France
| | - R. Kobayashi
- UT M. D. Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, villejuif, France; M.D. Anderson Cancer Center, houston, TX; Marseille University, Marseille, France
| | - L. Pusztai
- UT M. D. Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, villejuif, France; M.D. Anderson Cancer Center, houston, TX; Marseille University, Marseille, France
| |
Collapse
|
11
|
Abstract
BACKGROUND To review the efficacy of chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy when used in addition to hormonal therapy for the optimal management of estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-positive (HER2+) breast cancer. DESIGN Literature published from January 2003 to March 2008 was reviewed to assess the use of chemotherapy and biologic therapy in addition to hormonal agents. RESULTS Aromatase inhibitors (AIs) demonstrated greater effectiveness in the adjuvant setting than tamoxifen for the management of ER+ and HER2+ breast cancer. Evidence of cross talk between HER2- and ER-signaling pathways suggests that combined treatment with HER2 blockade and hormonal therapy may offer clinical advantages beyond those provided by hormonal therapy alone in ER+/HER2+ disease. Combined therapy with trastuzumab plus an aromatase AI significantly improves progression-free survival, response rates, and clinical benefits when compared with AI monotherapy in postmenopausal women. Several large studies demonstrated that trastuzumab significantly improves disease-free and overall survival when given in combination with, or following, chemotherapy, regardless of hormone receptor status. CONCLUSIONS HER2-targeted therapy maybe combined with AIs for the treatment of ER+/HER2+ metastatic breast cancer in postmenopausal women. HER2-targeted therapy in combination with AIs for treatment of ER+/HER2+ early breast cancer needs to be prospectively evaluated.
Collapse
Affiliation(s)
- A U Buzdar
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
| |
Collapse
|
12
|
Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 2008; 19:2020-5. [PMID: 18667396 DOI: 10.1093/annonc/mdn427] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The aim of this study was to compare the extent of pathologic response in patients with HER2-positive (HER2+) breast cancer treated with standard neoadjuvant chemotherapy, with or without trastuzumab (H), according to hormone receptor (HR) status. PATIENTS AND METHODS We included 199 patients with HER2+ breast cancer from three successive cohorts of neo-adjuvant chemotherapy on the basis of paclitaxel (Taxol) (P) administered weekly (w) or three weekly (3-w), followed by 5-fluorouracil (F), doxorubicin (A) or epirubicin (E), and cyclophosphamide (C). Residual cancer burden (RCB) was determined from pathologic review of the primary tumor and lymph nodes and was classified as pathologic complete response (pCR) or minimal (RCB-I), moderate (RCB-II), or extensive (RCB-III) residual disease. RESULTS In HR-positive (HR+) cancers, a higher rate of pathologic response (pCR/RCB-I) was observed with concurrent H + 3-wP/FEC (73%) than with 3-wP/FEC (34%, P = 0.002) or wP/FAC (47%; P = 0.02) chemotherapy alone. In HR-negative (HR-) cancers, there were no significant differences in the rate of pathologic response (pCR/RCB-I) from 3-wP/FAC (50%), wP/FAC (68%), or concurrent H + 3-wP/FEC (72%). CONCLUSIONS Patients with HR+/HER2+ breast cancer obtained significant benefit from addition of trastuzumab to P/FEC chemotherapy; pathologic response rate was similar to that seen in HR-/HER2+ breast cancers.
Collapse
Affiliation(s)
- F Peintinger
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer 2008; 99:68-71. [PMID: 18560403 PMCID: PMC2453019 DOI: 10.1038/sj.bjc.6604443] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Collagen IV is a major component of the vascular basement membrane and may be a marker of angiogenesis. Serum levels of this protein are elevated in some human cancers. Our objectives were to compare collagen IV levels in the serum of breast cancer patients and healthy women and to examine changes during preoperative chemotherapy. Sera from 51 patients with stage II–III breast cancer and 55 healthy controls were analysed. Collagen IV level was measured by a commercially available sandwich enzyme link immunoassay. Baseline serum levels were compared between cancer patients and healthy women and paired pre- and post-chemotherapy measurements were also performed in 39 patients who received preoperative chemotherapy and were correlated with response to therapy. The median serum collagen IV concentration was significantly higher in cancer patients (166 μg l−1) than in healthy women (115 μg l−1), P<0.001. Chemotherapy induced a significant further increase in serum collagen IV (167 μg l−1 prechemo vs 206 μg l−1 postchemo, P=0.001). There were no correlations between baseline collagen IV levels and response to therapy, age, clinical stage or HER2 status. In conclusion, patients with breast cancer have elevated levels of collagen IV compared to healthy women and collagen IV levels increase further during chemotherapy.
Collapse
Affiliation(s)
- C Mazouni
- Laboratoire de transfert biologique et oncologique, Marseille University, Houston, TX, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Buzdar AU, Cuzick J. Is overall survival an appropriate endpoint in early breast cancer studies? Data from the ATAC study at 100-month median follow-up. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.552] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Hubbard R, Peintinger F, Liedtke C, Hatzis C, Kuerer HM, Valero V, Buzdar AU, Hortobagyi GN, Pusztai L, Symmans WF. Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Litton JK, Gonzalez AM, Warneke CL, Kau S, Buzdar AU, Bondy M, Mahabir S, Hortobagyi GN, Brewster A. Body mass index and response to neoadjuvant chemotherapy in breast cancer patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
531 Background: Obesity in breast cancer patients is associated with increased risk of poor outcome. One possible mechanism is that obesity may affect metabolism of chemotherapeutic agents, influencing tumor response to chemotherapy. To test this hypothesis, we evaluated the relationship between body mass index (BMI, weight kg/height m2) and response to neoadjuvant chemotherapy in women diagnosed with operable breast cancer. Methods: From May 1990 - July 2004, 1169 patients diagnosed with invasive breast cancer at our institution, received neoadjuvant chemotherapy (anthracycline and/or taxane) followed by definitive surgery. Based on BMI, patients were categorized as obese (BMI ≥30), overweight (BMI 25 to <30), normal weight (18.5 to <25) and underweight (BMI <18.5). We used logistic regression to examine associations between BMI and pathologic response to therapy (complete= no invasive carcinoma, and partial) as well as tumor characteristics. Kaplan-Meier survival curves for BMI groups were compared using the log-rank test. Results: Median patient age was 50 (range 23 - 84) years; 30% were obese, 32% overweight, 36% normal weight and 1% underweight. BMI was not significantly associated with pathologic response to neoadjuvant chemotherapy even after adjusting for relevant clinical factors (OR 1.00; 95% CI 0.96–1.03, p = 0.8). Compared to patients not overweight, obese patients had higher odds of having ER negative tumors (OR 1.5; 95% CI 1.1–2.0; p = 0.01) and T3 or T4 lesions (OR 1.7; 95% CI 1.3–2.4, p < 0.001) adjusting for age, race and menopausal status. At a median follow up of 4.1 (range 0.2–14.3) years, obesity was significantly associated with poorer overall survival (p = 0.006) but not progression-free survival. Conclusions: Obese patients presented with more aggressive tumor characteristics and had worse overall survival compared to patients not overweight. However, BMI was not related to lower tumor response to anthracycline and/or taxane based neoadjuvant chemotherapy suggesting a role for other co-morbidities in influencing outcome. Understanding specific components through which overweight and obesity contribute to breast cancer outcome is essential to individualize and improve care of overweight/obese breast cancer patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. K. Litton
- Univ of Texas/ MD Anderson Cancer Ctr, Houston, TX
| | | | | | - S. Kau
- Univ of Texas/ MD Anderson Cancer Ctr, Houston, TX
| | - A. U. Buzdar
- Univ of Texas/ MD Anderson Cancer Ctr, Houston, TX
| | - M. Bondy
- Univ of Texas/ MD Anderson Cancer Ctr, Houston, TX
| | - S. Mahabir
- Univ of Texas/ MD Anderson Cancer Ctr, Houston, TX
| | | | - A. Brewster
- Univ of Texas/ MD Anderson Cancer Ctr, Houston, TX
| |
Collapse
|
17
|
Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 2007; 18:874-80. [PMID: 17293601 DOI: 10.1093/annonc/mdm008] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND We examined if inclusion of a taxane and more prolonged preoperative chemotherapy improves pathologic complete response (pCR) rate in estrogen receptor (ER)-positive breast cancer compared with three to four courses of 5-fluorouracil, doxorubicin, cyclophosphamide (FAC). PATIENTS AND METHODS Pooled analysis of results from seven consecutive neo-adjuvant chemotherapy trials including 1079 patients was carried out. These studies were conducted at MD Anderson Cancer Center from 1974 to 2001. Four hundred and twenty-six (39.5%) patients received taxane-based neo-adjuvant therapy. pCR rates and survival times were analyzed as a function of chemotherapy regimen and ER status. Multivariate logistic and Cox regression analysis were carried out to identify variables associated with pCR and survival. RESULTS Patients with ER-negative cancer had higher overall pCR rate than patients with ER-positive tumors (20.1% versus 4.9%, P < 0.001). In ER-negative patients, the pCR rates were 29% and 15% with and without a taxane (P < 0.001). In ER-positive patients, the pCR rates were 8.8% and 2.0% with and without a taxane (P < 0.001). In multivariate analysis, clinical tumor size (P < 0.001), ER-negative status (P < 0.001) and inclusion of a taxane (P = 0.01) were independently associated with pCR. For patients with pCR, survival was similar regardless of ER status or the type of regimen that induced pCR. CONCLUSION pCR rates increased for patients with both ER-positive and ER-negative tumors as regimens started to include a taxane and became longer. This indicates that a subset of patients with ER-positive breast cancer benefits from more aggressive chemotherapy, similarly to patients with ER-negative tumors.
Collapse
Affiliation(s)
- C Mazouni
- Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Esteva FJ, Anderson K, Lin F, Nahta R, Mejia J, Altundag K, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. Pharmacogenomic analysis of HER2 amplified breast cancer treated with preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide (T/FEC) chemotherapy. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.545] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
545 Background: We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and T/FEC chemotherapy. Methods: Pretreatment fine needle aspirations from 21 patients with HER2 amplified, stages II-III breast cancer were available for transcriptional profiling with Affymetrix U133 A chips. Results: Overall pathologic complete response (pCR) rate was 71%. Age, nuclear grade, tumor size, nodal status or quantitative estrogen and HER2 receptor mRNA expression showed no association with response in univariate and multivariate logistic regression. We tested the accuracy of a 30-gene pCR predictor that was previously developed from patients who received T/FEC only preoperative chemotherapy. This predictor was accurate in validation in T/FEC treated patients (n=51) but showed low sensitivity in patients who also received trastuzumab (sensitivity 53% versus 92%). We could not identify any differentially expressed genes between pCR (n=15) and residual disease (RD, n=6) at a false discovery rate (FDR) <90% in the HER2 amplified trastuzumab-treated cases. Hierarchical clustering using the “Perou intrinsic gene set” also failed to separate pCR from RD. Gene Set Enrichment Analysis with 22 genes from trastuzumab-resistant cell lines showed a modest association with RD (FDR=9%). Conclusions: Clinical variables and pharmacogenomic predictors that predict pCR in the absence of trastuzumab are no longer accurate when trastuzumab is included in the treatment. Trastuzumab-resistance associated genes identified in vitro are also associated with resistance in vivo. Support: Ellence Foundation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - K. Anderson
- UT M. D. Anderson Cancer Center, Houston, TX
| | - F. Lin
- UT M. D. Anderson Cancer Center, Houston, TX
| | - R. Nahta
- UT M. D. Anderson Cancer Center, Houston, TX
| | - J. Mejia
- UT M. D. Anderson Cancer Center, Houston, TX
| | - K. Altundag
- UT M. D. Anderson Cancer Center, Houston, TX
| | | | | | | | - L. Pusztai
- UT M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
19
|
Abstract
551 Background: Aromatase inhibitors have been associated with higher rates of adverse events associated with the joints, or ‘joint symptoms’ (JS) than tamoxifen. Details of these were reviewed in the ATAC study. JS were reported spontaneously at a higher frequency with anastrozole (A) than with tamoxifen (T), and here we present a detailed assessment of these events. Methods: Adverse events related to the joints were coded into four COSTART terms: arthralgia, arthritis, arthrosis and joint disorder. Time of onset, duration of symptoms and their effect on treatment adherence were reviewed. Results: At 68 months’ median follow-up 1100/3092 (35.6%) patients in the A arm and 911/3094 (29.4%) patients in the T arm experienced JS. Almost half (46%) of patients with JS reported these as an exacerbation of a pre-existing condition in the joints and in most cases the location was generalized. The majority of first events developed within 24 months of initiation of treatment (A 68%, T 59%) with a peak occurrence at 6 months (A 29%, T 20%). Review of all available data showed that half of the patients who recovered from JS were symptom-free within 6 months of onset and in 75%, symptoms resolved within 18 months. Median time to resolution for these events was 5.5 months for the A arm and 5.9 months for the T arm. Sixty percent of patients experiencing JS received treatment, with >90% of these patients managed with an NSAID alone or in combination with mild analgesics. Although the difference in overall prevalence between treatment arms was statistically significant (p<0.0001), a similar occurrence of serious adverse events of JS was reported (A 10.6%, T 10.4%), and only a small number of patients experiencing JS required treatment withdrawal (A 2.1%, T 0.9%). Conclusion: 68-month data from the ATAC trial showed that treatment with A was associated with a modest increase in the incidence of JS compared with T. In most patients the events were mild-to-moderate in intensity and did not lead to withdrawal of treatment. [Table: see text]
Collapse
|
20
|
|
21
|
Yamaya H, Yoshida K, Kuritani J, Yonezawa J, Yonezawa JI, Tsuda M, Shindo T, Nagayama S, Buzdar AU. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose. J Clin Pharm Ther 2005; 30:459-70. [PMID: 16164493 DOI: 10.1111/j.1365-2710.2005.00673.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVES The present study was conducted to evaluate the safety, tolerability, and pharmacokinetics of TAS-108 after ascending single oral doses and to analyse preliminarily the effect of food on the pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects. METHODS Twelve healthy subjects participated in an open-label, ascending single-dose, alternating group, safety, tolerance, and pharmacokinetic study of TAS-108 administered orally to two groups of the subjects, one given alternating doses of 10, 40, 120 mg (group A) and the other of 20, 80, 160 mg (group B), in the fasting state. In addition, six subjects (group A) were administered an additional dose at 120 mg TAS-108 after food consumption. Plasma and urine samples for measurement of TAS-108 were analysed by validated analytical procedures using a liquid chromatographic method with tandem mass spectrometric detection (LC/MS/MS). RESULTS There was no dose-dependent increase in any adverse events (AEs), and there were no serious AEs or deaths. TAS-108 was readily absorbed following oral administration of the 80-, 120- and 160-mg doses. Plasma TAS-108 levels steadily declined, generally in a mono-exponential manner, with overall mean t(1/2) values ranging from 3.04 to 4.43 h in the fasting groups. Administration of TAS-108 after a high-fat meal markedly increased the bioavailability of the drug. The mean C(max) and AUC(0--t) values increased after a high-fat breakfast by 182 and 191% compared with the fasting value respectively. CONCLUSIONS In this escalating dose study of TAS-108, the drug was well tolerated by the participants. The maximum and systemic exposure to TAS-108 tended to increase with increasing dose and its bioavailability markedly increased after high-fat food intake.
Collapse
Affiliation(s)
- H Yamaya
- Pharmacokinetics Research Laboratory, Taiho Pharmaceutical Co., Ltd, Tokushima, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Buzdar AU. Impact of adjuvant chemotherapy prior to endocrine therapy: 68 month results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.608] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Altundag K, Kim E, Broglio K, Buzdar AU, Hortobagyi GN, Arun B. Characterization of bone mineral density (BMD) at the time of diagnosis in postmenopausal patients with operable breast cancer: Association with clinical-pathological findings. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9611] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Altundag
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | - E. Kim
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | - K. Broglio
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | - A. U. Buzdar
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | | | - B. Arun
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| |
Collapse
|
24
|
Hanrahan EO, Frye D, Buzdar AU, Theriault RL, Booser DJ, Valero V, Singletary SE, Gajewski JL, Champlin RE, Hortobagyi GN. Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.663] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - D. Frye
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | - A. U. Buzdar
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | | | - D. J. Booser
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | - V. Valero
- Univ of Texas M. D. Anderson Cancer Ctr, Houston, TX
| | | | | | | | | |
Collapse
|
25
|
Buzdar AU, Hunt K, Smith T, Francis D, Ewer M, Booser D, Singletary E, Buchholz T, Sahin A, Hortobagyi GN. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.520] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - K. Hunt
- M. D. Anderson Cancer Center, Houston, TX
| | - T. Smith
- M. D. Anderson Cancer Center, Houston, TX
| | - D. Francis
- M. D. Anderson Cancer Center, Houston, TX
| | - M. Ewer
- M. D. Anderson Cancer Center, Houston, TX
| | - D. Booser
- M. D. Anderson Cancer Center, Houston, TX
| | | | | | - A. Sahin
- M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
26
|
Hennessy BTJ, Kuerer H, Sahin A, Buzdar AU, Kau SW, Singletary SE, Hortobagyi GN, Valero V. Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - H. Kuerer
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - A. Sahin
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - A. U. Buzdar
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - S. W. Kau
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | | | | - V. Valero
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
27
|
Valero V, Gill E, Paton V, Chang HY, Buzdar AU, Park G, Hortobagyi G, Ewer M. Normal cardiac biopsy results following co-administration of doxorubicin (A), Cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.572] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- V. Valero
- University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Washington, Seattle, WA; Genentech, Inc, So. San Francisco, CA
| | - E. Gill
- University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Washington, Seattle, WA; Genentech, Inc, So. San Francisco, CA
| | - V. Paton
- University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Washington, Seattle, WA; Genentech, Inc, So. San Francisco, CA
| | - H.-Y. Chang
- University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Washington, Seattle, WA; Genentech, Inc, So. San Francisco, CA
| | - A. U. Buzdar
- University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Washington, Seattle, WA; Genentech, Inc, So. San Francisco, CA
| | - G. Park
- University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Washington, Seattle, WA; Genentech, Inc, So. San Francisco, CA
| | - G. Hortobagyi
- University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Washington, Seattle, WA; Genentech, Inc, So. San Francisco, CA
| | - M. Ewer
- University of Texas M.D. Anderson Cancer Center, Houston, TX; University of Washington, Seattle, WA; Genentech, Inc, So. San Francisco, CA
| |
Collapse
|
28
|
Hortobagyi GN, Kau SW, Buzdar AU, Theriault RL, Booser DJ, Gwyn K, Valero V. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.585] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - S.-W. Kau
- UT M. D. Anderson Cancer Center, Houston, TX
| | | | | | | | - K. Gwyn
- UT M. D. Anderson Cancer Center, Houston, TX
| | - V. Valero
- UT M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
29
|
Gonzalez-Angulo AM, Kau SW, Broglio K, Buzdar AU, Theriault RL, Valero V, Sneige N, Frye D, Hortobagyi GN, Cristofanilli M. Invasive lobular carcinoma (ILC) “classic type”: Distinct clinical features. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.663] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - S. W. Kau
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - K. Broglio
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - A. U. Buzdar
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | | | - V. Valero
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - N. Sneige
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - D. Frye
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | | | | |
Collapse
|
30
|
Buchholz TA, Woodward WA, Tucker SL, Strom EA, Hunt KK, Buzdar AU, Perkins GH, Schechter NR, Hortobagyi GN. Defining the competing risk of local-regional and distant recurrence in 1,256 patients treated with mastectomy and doxorubicin-based adjuvant chemotherapy. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. A. Buchholz
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - W. A. Woodward
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - S. L. Tucker
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - E. A. Strom
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - K. K. Hunt
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - A. U. Buzdar
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - G. H. Perkins
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | - N. R. Schechter
- University of Texas M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
31
|
Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 2002; 7:171-7. [PMID: 11692142 DOI: 10.1007/bf03032345] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The purpose of this study was to investigate the frequency of expression of the erbB/HER family of growth factor receptors, their ligand heregulin, and the two different signaling pathways p38 and mitogen-activated protein kinase (MAPK), as well as the status of HER-2 phosphorylation in tumor specimens from patients with primary breast cancer. The level of expression of these proteins was measured by quantitative immunohistochemistry combined with microscope-based image analysis in paraffin-embedded breast cancer tissue from 35 patients. The frequency of expression was: EGFR (51%), HER-2 (54%), P-HER-2 (48%), HER-3 (48%), HER-4 (57%), heregulin (48%), p38 (17%), MAPK (48%). There was evidence of associations among the coexpression of heregulin, EGFR, HER-2, and HER-3. Also, there was evidence of a positive association between P-MAPK and HER-4. HER-3 was expressed at high levels in patients younger than 50 years of age. There was a trend for expression of higher levels of HER-4 in tumors larger than 2 cm. The expression of EGFR, HER-2, heregulin, p38 and MAPK was independent of age, tumor size, number of lymph nodes involved or hormone receptor status. The HER family of growth factor receptors appear to be regulated independently in invasive breast cancer. Assessing the expression of multiple tumor markers by quantitative immuno-histochemistry is feasible. Further research is needed to determine the prognostic and predictive roles of the various associations between HER receptors, their ligands and signal transduction molecules in patients with early-stage breast cancer.
Collapse
Affiliation(s)
- F J Esteva
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Combination endocrine therapy has long been sought after as a means to better treat breast cancer. Agents that suppress estrogen production are given with agents that suppress estrogenic activity at the cellular level. Historically, these combinations have resulted in initial improvements in response rates, but relapse-free and overall survival were not significantly improved. Also, the increased toxicity seen with these regimens was limiting. New endocrine therapies with more potent activity and less toxicity have led to a resurgence of this idea in the management of breast cancer. Complete estrogen blockade has been compared with single-agent treatments in many different settings. The endocrine effects of this type of therapy are intriguing, but apparently do not readily predict a clinical advantage. The combination of an aromatase inhibitor and an antiestrogen, despite pharmacokinetic interactions, may prove to be beneficial. Results from ongoing trials are eagerly awaited to further address this question in postmenopausal breast cancer patients. For premenopausal breast cancer patients the options are more complex. Clinical outcomes with leutinizing hormone releasing hormone (LHRH) agonists plus aromatase inhibitors are limited to very small phase II studies and are not clearly superior to single-agent therapy. Clinical data in the metastatic setting with premenopausal patients favor the use of an LHRH agonist with tamoxifen over the use of an LHRH agonist alone. However, a similar comparison with tamoxifen alone is lacking with only one trial including this as a treatment arm. Adjuvant therapy with this combined endocrine approach (LHRH agonist plus antiestrogen) has been more extensively studied, but lacks crucial comparisons necessary for making complex treatment decisions. Hopefully, through investigative diligence and ingenuity this issue can be adequately understood. However, many exciting new agents are on the horizon that offer hope to further advance the progress made to date although further confounding the questions already answered.
Collapse
Affiliation(s)
- L B Michaud
- The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | |
Collapse
|
33
|
Buzdar AU, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS. Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res 2001; 7:4335s-4337s; discussion 4411s-4412s. [PMID: 11916221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Affiliation(s)
- A U Buzdar
- University of Texas M. D. Anderson Cancer Center, Houston 77030-4009, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
The new generation of selective aromatase inhibitors (anastrozole, letrozole and exemestane) offer a significant efficacy and safety advantage over both older agents in this class (aminoglutethimide) and the progestins (megestrol acetate (MA)), as second-line treatment for postmenopausal women with advanced hormone-dependent breast cancer who have failed on tamoxifen therapy. Exemestane, a steroidal aromatase inhibitor, has been shown to have activity after failure with the non-steroidal aromatase inhibitors, anastrozole and letrozole, and could be used as third-line treatment. Although the newer aromatase inhibitors belong to the same class and appear, from indirect comparisons, to have similar efficacy compared with the older therapies, they have different pharmacokinetic and pharmacodynamic profiles, suggesting the potential for clinical differences. Compared with exemestane and letrozole, anastrozole shows greater selectivity for aromatase, as it lacks any evidence of an effect on adrenal steroidogenesis and has no androgenic effects. Therefore, it is clear that these agents should not be considered to be similar in all respects. In summary, the introduction of the aromatase inhibitors represents a significant step forward in the treatment of advanced breast cancer in postmenopausal women. Studies in the adjuvant setting will ultimately determine whether the differences in pharmacokinetics and phamacodynamics will be of clinical relevance.
Collapse
Affiliation(s)
- A U Buzdar
- Department of Breast Medical Oncology, M.D. Anderson Cancer Center, M.D. University of Texas, Box 424, 1515 Holcombe Blvd, Houston, TX 77030, USA.
| |
Collapse
|
35
|
Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg 2001; 182:601-8. [PMID: 11839324 DOI: 10.1016/s0002-9610(01)00793-0] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND This study was performed to investigate the extent of tumor downstaging achieved in women with operable breast cancer treated with neoadjuvant chemotherapy and breast-conservation surgery, develop recommendations for effective surgical planning, and report local-regional recurrence rates with this approach. METHODS One hundred nine patients with stage II or III (T3N1) breast cancer were treated in three prospective trials utilizing four cycles of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC, n = 72) or paclitaxel (n = 37) followed by segmental resection (n = 109) and axillary node dissection (n = 94). Postoperatively, patients received 4 additional cycles of FAC followed by irradiation of the breast. The median follow-up was 53 months. RESULTS The median tumor size was 4 cm (range 1.1 to 9 cm) at presentation and only 1 cm (range 0 to 4.5 cm) after four cycles of chemotherapy. The primary tumor could not be palpated after chemotherapy in 55% of 104 patients presenting with a palpable mass and therefore required needle localization or ultrasound guidance for surgical resection. Of the 34 patients clinically deemed to have no residual carcinoma in the breast after chemotherapy and before surgery, only 50% of these patients were found to have no residual carcinoma on pathologic examination after surgery. Patients with primary tumors < or =2 cm were significantly more likely than patients with larger tumors to have complete eradication of the primary tumor prior to surgery (P <0.001). The 5-year local-regional recurrence rate was 5%. CONCLUSIONS Tumor downstaging is marked in patients with operable breast cancer and requires close monitoring during chemotherapy. We recommend placement of metallic tumor markers when the primary tumor is < or =2 cm to facilitate adequate resection and pathologic processing. Resection of the tumor bed remains necessary in women deemed to have a complete clinical response to ensure low rates of recurrence.
Collapse
Affiliation(s)
- H M Kuerer
- Department of Surgical Oncology, Box 444, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 2001; 92:2523-8. [PMID: 11745185 DOI: 10.1002/1097-0142(20011115)92:10<2523::aid-cncr1603>3.0.co;2-6] [Citation(s) in RCA: 120] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND The objective of this study was to analyze the outcome of treatment in young women with breast carcinoma who were treated at a single institution and to develop a clearer understanding of the natural history of the disease in these women. METHODS One hundred eighty-five women age < or = 30 years in whom a diagnosis of invasive breast carcinoma was made between October 1985 and September 1995 were identified in the Tumor Registry data base. Patient data were obtained by chart review. All female patients with breast carcinoma who were age > 30 years and who were identified in the same data base and received treatment during the same period served as the control population. The stage-stratified overall survival (OS) rate for the study patients was compared with the OS rate for both the control population and patients in the National Cancer Data Base (NCDB). RESULTS Of 185 patients, 11% presented with Stage I disease, 45% presented with Stage II disease, 38% presented with Stage III disease, and 6% presented with Stage IV disease. Twenty-nine percent of patients with Stage I disease received adjuvant therapy, and 84% of patients with Stage II disease and 96% of patients with Stage III disease received either adjuvant or neoadjuvant chemotherapy. Among patients with Stage I disease, 8 patients underwent mastectomy and 13 patients underwent breast-conserving surgery (BCS). Among patients with Stage II disease, 66 patients underwent mastectomy and 17 patients underwent BCS. Among patients with Stage III disease, 65 patients underwent mastectomy and 5 patients underwent BCS. The 5-year OS rate was 87% for patients with Stage I disease, 60% for patients with Stage II disease, 42% for patients with Stage III disease, and 16% for patients with Stage IV disease. Compared with the control patients and those in the NCDB, there was a trend toward worse OS rates in women age < or = 30 years. CONCLUSIONS Women who are diagnosed with breast carcinoma at an age < or = 30 years appear to have a poorer prognosis compared with that for their older counterparts.
Collapse
Affiliation(s)
- Q Xiong
- Division of Cancer Medicine; University of Texas M. D. Anderson Cancer Center; Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
Anastrozole (Arimidex) is a third-generation aromatase inhibitor which has been shown to possess superior efficacy and tolerability over established endocrine agents in advanced breast cancer. Inhibition of aromatase prevents the conversion of androgen substrates to oestrogen, its sole source in postmenopausal women, thereby leading to regression of hormone-sensitive breast carcinomas. Clinical pharmacology data indicate that anastrozole is a potent aromatase inhibitor, providing near-maximal suppression of serum and intratumoural oestrogens to below detectable levels. Anastrozole may offer greater selectivity compared with other aromatase inhibitors, being without any intrinsic endocrine effects and with no apparent effect on the synthesis of adrenal steroids. It is well tolerated and has a convenient once-daily dosing regimen, ensuring maximum patient compliance. A major clinical programme has demonstrated that anastrozole is superior to the standard endocrine therapy, tamoxifen, for the first-line treatment of postmenopausal women with hormone-sensitive advanced breast cancer. Its superior efficacy in advanced disease, together with its improved tolerability and convenient dosage, make it a suitable agent to be assessed for the treatment of early breast cancer in postmenopausal women. This was investigated in the largest single adjuvant breast cancer study ever to be carried out, the ATAC (Arimidex, tamoxifen, alone or in combination) trial, which has now completed recruitment, with the first efficacy and safety data awaited.
Collapse
Affiliation(s)
- A U Buzdar
- Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston 77030, USA
| |
Collapse
|
38
|
Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001; 92:1775-82. [PMID: 11745249 DOI: 10.1002/1097-0142(20011001)92:7<1775::aid-cncr1693>3.0.co;2-e] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Inflammatory breast carcinoma (IBC) is a rare but aggressive form of breast carcinoma. Anthracycline-based regimens represent the standard of treatment for IBC. Reports of significant clinical activity of paclitaxel in metastatic breast carcinoma led the authors to investigate the role of this drug in the management of IBC. METHODS Forty-four patients with IBC were enrolled between February 1994 and January 1998. The treatment plan consisted of induction chemotherapy (IC), mastectomy, adjuvant chemotherapy, and radiotherapy. Forty-two patients received IC with four cycles of fluorouracil, doxorubicin, and cyclophosphamide. If the clinical response was less than partial, patients were "crossed over" to paclitaxel before mastectomy. All patients received adjuvant paclitaxel. Patients unresectable after paclitaxel were offered high-dose chemotherapy with autologous peripheral blood progenitor cell support. RESULTS Thirty-four patients (81%) achieved an objective clinical remission; 3 patients (7%) achieved a clinical complete remission, 31 (74%) a partial remission. Six patients (14%) achieved pathologic complete remission. Sixteen patients were treated with paclitaxel, 7 of them (44%) were able to undergo mastectomy. Median time to progression (TTP) was 22 months. Median overall survival (OS) was 46 months. Concordance between clinical and pathologic response was documented in only 8 patients (24%). No differences in TTP and OS compared with a historical group of 178 IBC patients treated with anthracycline-based regimens. CONCLUSIONS Paclitaxel improves tumor resectability in anthracycline-refractory IBC. The impact of paclitaxel on the prognosis of IBC needs to be better evaluated in future trials using more dose-intensive schedules of administration. New imaging modalities may contribute to improve assessment of response to IC.
Collapse
Affiliation(s)
- M Cristofanilli
- Department of Breast Medical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 2001; 7:413-20. [PMID: 11693900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
PURPOSE The purpose of this study was to determine the clinical, pathological, and treatment factors that are predictive of local-regional recurrence and overall survival for patients with breast cancer that is refractory to neoadjuvant chemotherapy. PATIENTS AND METHODS This study analyzed the data of the 177 breast cancer patients treated on our institutional protocols who had less than a partial response to neoadjuvant chemotherapy. The initial clinical stage of disease was II in 27%, III in 69%, and IV (supraclavicular lymph node involvement) in 4%. Surgery was performed in 94% of the patients, and 77% of these patients also received adjuvant chemotherapy. RESULTS After a median follow-up of 5.2 years, 106 patients experienced disease recurrence, with 98 of these having distant metastases and 45 having local-regional recurrence. The 5- and 10-year overall survivals for the entire group were 56% and 33%, respectively. The factors that were independently associated with a statistically significant poorer overall survival in a Cox regression analysis were pathologically involved lymph nodes after surgery, estrogen receptor-negative disease, and progressive disease during neoadjuvant chemotherapy. The 5-year overall survival for patients with pathologically negative lymph nodes ranged from 84% (estrogen receptor-positive disease) to 75% (estrogen re-ceptor-negative disease), compared with rates for patients with pathologically positive lymph nodes of 66% (estrogen receptor-positive disease) and 40% (estrogen receptor-negative disease). The 5-year survival of patients with progressive disease was only 19%. The 5- and 10-year local-regional recurrence rates for the 177 patients were 27% and 34%, respectively. Significant factors on Cox analysis that predicted for local-regional recurrence were four or more pathologically involved lymph nodes and estrogen receptor-negative disease. For the 105 patients treated with surgery and postoperative radiation therapy, the 10-year local-regional recurrence rates for the subgroups with 0, 1, or 2 of these factors were 12%, 25%, and 44%, respectively. CONCLUSIONS For patients with a poor response to neoadjuvant chemotherapy, conventional treatments achieve reasonable outcomes in those with lymph node-negative disease or estrogen receptor-positive disease. However, more active systemic and local therapies are needed for patients with estrogen receptor-negative disease and positive lymph nodes and for those with clinical evidence of progressive disease during neoadjuvant chemotherapy.
Collapse
Affiliation(s)
- T A Buchholz
- Department of Radiation Oncology,The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 2001; 19:459-66. [PMID: 11458813 DOI: 10.1081/cnv-100103844] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Vinorelbine (Navelbine) has significant activity against breast carcinoma and is less neurotoxic than vinblastine. Because vinblastine has improved activity when administered by continuous infusion, we conducted a Phase I-II study to determine the maximum tolerated dose (MTD) of vinorelbine when given by continuous infusion and the response rates to it in heavily pretreated metastatic breast cancer patients. Between April 1994 and August 1997, 87 patients were entered in the study. All were female and had proven metastatic breast cancer. Ninety-five percent of them had received prior doxorubicin treatment, and 74% had received prior paclitaxel treatment. In Phase I of the study, all patients received 8 mg of vinorelbine by intravenous (i.v.) bolus followed by a continuous infusion of vinorelbine over 96 hr. When the MTD was determined, patients were entered in the Phase II arm to assess treatment responses and cumulative toxic reactions. In the Phase I arm (43 patients, 182 cycles), we determined the MTD of vinorelbine to be 8 mg by i.v. bolus followed by a continuous infusion of 11 mg/m2/day over 4 days. The dose-limiting toxic reaction was grade 3-4 granulocytopenia in 35% of the cycles and neutropenic fever in 15% of the cycles. Forty-four patients (193 cycles) were treated at the MTD. Seven (16%) of them had a response (2 complete responses, 5 partial responses). The median durations of response and survival were 4.3 and 8.6 months, respectively. However, cumulative toxic reactions (neutropenic fever and stomatitis) in 22 patients (50%) required dose reductions. A continuous infusion of vinorelbine can be safely administered but with a narrow therapeutic index because of cumulative toxic reactions. We recommend a modified MTD of vinorelbine: 8 mg by i.v. bolus followed by a continuous infusion of 10 mg/m2/day over 4 days. However, this treatment schedule offers no apparent advantage over the commonly used weekly vinorelbine schedule.
Collapse
Affiliation(s)
- N K Ibrahim
- Division of Medicine, Department of Breast Medical Oncology, Box 56, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Chemotherapy plays an important role in the management of metastatic breast cancer. The anthracyclines (doxorubicin, epirubicin) and the taxanes (paclitaxel, docetaxel) are considered the most active agents for patients with advanced breast cancer. Traditionally, the anthracyclines have been used in combination with cyclophosphamide and 5-fluorouracil (FAC, FEC). The taxanes have single-agent activity similar to older combination chemotherapy treatments. There is great interest in developing anthracycline/taxane combinations. Capecitabine is indicated for patients who progress after anthracycline and taxane therapy. Vinorelbine and gemcitabine have activity in patients with metastatic breast cancer and are commonly used as third- and fourth-line palliative therapy. The role of high-dose chemotherapy is not well-defined and remains experimental. Novel cytotoxic therapy strategies include the development of anthracycline, taxane, and oral fluoropyrimidine analogues; antifolates; topoisomerase I inhibitors, and multidrug resistance inhibitors. A better understanding of the biology of breast cancer is providing novel treatment approaches. Oncogenes and tumor-supressor genes are emerging as important targets for therapy. Trastuzumab, a monoclonal antibody directed against the Her-2/neu protein, has been shown to prolong survival in patients with metastatic breast cancer. Other novel biologic therapies interfere with signal transduction pathways and angiogenesis. The challenge for the next decade will be to integrate these promising agents in the management of metastatic and primary breast cancer.
Collapse
Affiliation(s)
- F J Esteva
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 56, Houston, TX 77030, USA.
| | | | | | | | | | | |
Collapse
|
42
|
Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC, Hunt KK, Ross MI, Buchholz TA, Buzdar AU, Singletary SE. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol 2001; 8:425-31. [PMID: 11407517 DOI: 10.1007/s10434-001-0425-6] [Citation(s) in RCA: 104] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND The objective of the study was to compare the treatment outcomes in patients with occult primary carcinoma with axillary lymph node metastasis who were treated with mastectomy or with intent to preserve the breast. METHODS From 1951 to 1998, 479 female patients were registered with axillary lymph node metastasis from an unknown primary. After clinical workup, including mammography, 45 patients retained this diagnosis and received treatment for T0 N1-2 M0 carcinoma of the breast. Clinical and pathological data were collected retrospectively, and survival was calculated from the date of initial diagnosis using the Kaplan-Meier method. Median follow-up time was 7 years. RESULTS Median age was 54 years (range, 32-79). Clinical nodal status was N1 in 71% and N2 in 29% of the patients. Surgical treatment was mastectomy in 29% and an intent to preserve the breast in 71% of the patients. Locoregional radiotherapy was used in 71% and systemic chemoendocrine therapy was used in 73% of the patients. Of the 13 mastectomy patients, only one had a primary tumor discovered in the specimen. Two patients (4%) were ultimately diagnosed with lung cancer and neuroendocrine tumor. No significant difference was detected between mastectomy and breast preservation in locoregional recurrence (15% versus 13%), distant metastases (31% versus 22%), or 5-year survival (75% vs. 79%). Regardless of surgical therapy, the most important determinant of survival was the number of positive nodes. Five-year overall survival was 87% with 1-3 positive nodes compared with 42% with > or =4 positive nodes (P < .0001). CONCLUSIONS Occult primary carcinoma with axillary metastases can be treated with preservation of the breast without a negative impact on local control or survival.
Collapse
Affiliation(s)
- G Vlastos
- Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol 2001; 77:139-47. [PMID: 11398169 DOI: 10.1002/jso.1085] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND AND OBJECTIVES The most powerful predictor of the response of breast cancers to hormonal therapy is the presence of estrogen receptors in the tumor cells. Estrogen receptors are expressed in approximately 35-55% of all breast tumors but up to 80-90% of tumors from women older than 55 years. METHODS At this time, tamoxifen remains the first-line hormonal therapy for breast cancer of all stages. However, the aromatase inhibitors are evolving into an important treatment option. Aromatase inhibitors prevent the conversion of precursors (androgens) to estrogens. RESULTS On the basis of several randomized clinical trials, aromatase inhibitors have become established as the second-line therapy for postmenopausal women with advanced breast cancer progressing during tamoxifen therapy. Furthermore, very recent trials support the use of these agents as first-line therapy in place of tamoxifen. CONCLUSIONS The roles of the selective aromatase inhibitors in the prevention of breast cancer and in the neoadjuvant and adjuvant treatment of early-stage breast cancer are the focus of several planned and ongoing large-scale clinical trials. These trials will answer some of the many questions that remain regarding optimal hormonal therapy for hormone-dependent breast cancer.
Collapse
Affiliation(s)
- H M Kuerer
- Department of Surgical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | |
Collapse
|
44
|
Abstract
The goals of treating patients with metastatic breast cancer are to prolong survival, slow or halt disease progression, and enhance the patient's quality of life. In patients with estrogen receptor (ER)-positive cancers that are not progressing rapidly, endocrine therapy is generally the first treatment option. If a patient initially responds to an endocrine agent and then progresses, another endocrine agent may still provide benefit. Tamoxifen has been used as first-line therapy for metastatic breast cancer for many years. Until recently, no other endocrine agent has shown superiority to tamoxifen in this setting. The nonsteroidal aromatase inhibitors, anastrozole and letrozole, have been widely accepted as second-line therapy after failure of tamoxifen; they have replaced megestrol acetate in this setting. Recently, anastrozole was shown to have at least equivalent efficacy and a superior side effect profile compared with tamoxifen for treating postmenopausal women in the first-line setting. Thus, this aromatase inhibitor has become a viable option for first-line therapy in postmenopausal women. Trials of letrozole in this setting are nearing completion. Exemestane has been shown to be an effective second-line agent and to have at least some efficacy as a third-line agent even after failure of a nonsteroidal aromatase inhibitor. Results are anxiously awaited from trials of new endocrine agents including the first member of a new class of endocrine agent, the estrogen-receptor downregulator class. Semin Oncol 28:291-304.
Collapse
Affiliation(s)
- A U Buzdar
- Department of Breast Medical Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77037, USA
| |
Collapse
|
45
|
Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva FJ, Newman L, Singletary SE, Buzdar AU, Hunt KK. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol 2001; 19:2240-6. [PMID: 11304777 DOI: 10.1200/jco.2001.19.8.2240] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine the impact of tamoxifen and chemotherapy on local control for breast cancer patients treated with breast-conservation therapy. PATIENTS AND METHODS The data from 484 breast cancer patients who were treated with breast-conserving surgery and radiation were analyzed. Only patients with lymph node-negative disease were studied to provide comparative groups with a similar stage of disease and a similar competing risk for distant metastases. Actuarial local control rates of the 277 patients treated with systemic therapy (128, chemotherapy with or without tamoxifen; 149, tamoxifen alone) were compared with the rates for the 207 patients who received no systemic treatment. Only 10% of the patients had positive (2%), close (3%), or unknown margin status (5%). RESULTS Patients treated with systemic therapy had improved 5-year (97.5% v 89.8%) and 8-year (95.6% v 85.2%) local control rates compared with those that did not receive systemic treatment (P =.004, log-rank test). There was no statistical difference in local control between patients treated with chemotherapy and patients treated with tamoxifen alone (P =.219). Systemic treatment, margin status, young patient age, estrogen and progesterone receptor status, and primary tumor size were analyzed in a Cox regression analysis. The use of systemic treatment was the most powerful predictor of local control: patients who did not receive systemic treatment had a relative risk of local recurrence of 3.3 (95% confidence interval, 1.5 to 7.5; P =.004). CONCLUSION In this retrospective analysis, systemic therapy appears to contribute to long-term local control in patients with lymph node-negative breast cancer treated with breast-conservation therapy.
Collapse
Affiliation(s)
- T A Buchholz
- Departments of Radiation Oncology, Biomathematics, Breast Medical Oncology, and Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Newman LA, Kuerer HM, Fornage B, Mirza N, Hunt KK, Ross MI, Ames FC, Buzdar AU, Singletary SE. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 2001; 181:313-8. [PMID: 11438265 DOI: 10.1016/s0002-9610(01)00588-8] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
BACKGROUND Ultrasonography is increasingly used to evaluate the nodal status of breast cancer patients and specialized positioning permits assessment of the infraclavicular fossa. However, the incidence and significance of infraclavicular (level III) adenopathy detected sonographically in locally advanced breast cancer (LABC) has not been defined. METHODS The study population consisted of 146 LABC patients registered in a prospective trial of induction chemotherapy between 1991 and 1996. All patients underwent ultrasound imaging before and after chemotherapy. Median follow-up was 32 months. RESULTS Forty-two of 146 patients (29%) had suspicious infraclavicular adenopathy; all 42 had additional positive axillary lymph nodes by ultrasound. Disease-free and overall survival for the patients with suspicious infraclavicular adenopathy was significantly worse compared with patients without this feature; disease-free survival 50% versus 68% (P = 0.112); overall survival 58% versus 83% (P = 0.026). CONCLUSIONS Nearly one third of LABC patients will have infraclavicular lymph node involvement by ultrasound imaging; this finding is a significant adverse prognostic feature, and we recommend that infraclavicular nodal evaluation become a routine component of the sonographic workup of breast cancer patients, particularly if lower axillary lymph nodes appear involved.
Collapse
Affiliation(s)
- L A Newman
- Department of Surgical Oncology, Box 444, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer 2001; 91:664-71. [PMID: 11241232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
BACKGROUND The purpose of the study was to determine the maximum tolerated dose (MTD) of vinorelbine and paclitaxel given concomitantly in patients with advanced breast carcinoma, the toxicity of this combination, and whether the addition of granulocyte colony-stimulating factor (G-CSF) would allow administration of higher doses of the combination. METHODS Between January 1994 and January 1995, 38 patients were entered on this study. All patients received vinorelbine and paclitaxel administered simultaneously over 3 hours and repeated every 21 days as frontline therapy for metastatic breast carcinoma. Twenty-five patients (Group 1) did not receive prophylactic G-CSF, and 13 patients (Group 2) received prophylactic G-CSF. Toxic effects were documented prospectively using the National Cancer Institute grading system. RESULTS One hundred eighty-seven (Group 1) and 111 (Group 2) cycles were administered. For Group 1, Grade 3-4 granulocytopenia was encountered in 72% of the cycles and neutropenic fever in 30% of the cycles. For Group 2, Grade 3-4 granulocytopenia and neutropenic fever were encountered in 23% and 4% of the cycles, respectively. Grade 3-4 fatigue and myalgia, respectively, were encountered in 11% and 3% of the cycles in Group 1, whereas they were reported in 12% and 1% of the cycles in Group 2. The MTD of this combination without prophylactic G-CSF was 25 mg/m2 of vinorelbine and 150 mg/m2 of paclitaxel, the dose-limiting toxicity (DLT) being neutropenic fever and myalgia. The MTD of this combination with G-CSF was 36 mg/m2 of vinorelbine and 150 mg/m2 of paclitaxel, the DLT being myalgia and fatigue. CONCLUSIONS The authors conclude that vinorelbine and paclitaxel can be safely administered concomitantly and are well tolerated. Phase II studies are recommended to test the efficacy of this schedule.
Collapse
Affiliation(s)
- N K Ibrahim
- Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
| | | | | | | | | | | |
Collapse
|
48
|
Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 2001; 19:628-33. [PMID: 11157012 DOI: 10.1200/jco.2001.19.3.628] [Citation(s) in RCA: 141] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE To determine outcomes in local-regional control, disease-free survival, and overall survival in patients with locally advanced breast cancer (LABC) who present with ipsilateral supraclavicular metastases and who are treated with combined-modality therapy. PATIENTS AND METHODS Seventy patients with regional stage IV LABC, which is defined by our institution as LABC with ipsilateral supraclavicular adenopathy without evidence of distant disease, received treatment on three prospective trials of neoadjuvant chemotherapy. All patients received neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil, or cyclophosphamide, doxorubicin, vincristine, and prednisone. Patients then received local therapy that consisted of either total mastectomy and axillary lymph node dissection (ALND) or segmental mastectomy and ALND before or after irradiation. Patients with no response to neoadjuvant chemotherapy were treated with surgery and/or radiotherapy. After completion of local therapy, chemotherapy was continued for four to 15 cycles, followed by radiotherapy. Patients older than 50 years who had estrogen receptor-positive tumors received tamoxifen for 5 years. RESULTS Median follow-up was 11.6 years (range, 4.8 to 22.6 years). Disease-free survival rates at 5 and 10 years were 34% and 32%, respectively. The median disease-free survival was 1.9 years. Overall survival rates at 5 and 10 years were 41% and 31%, respectively. The median overall survival was 3.5 years. The overall response rate (partial and complete responses) to induction chemotherapy was 89%. No treatment-related deaths occurred. CONCLUSION Patients with ipsilateral supraclavicular metastases but no other evidence of distant metastases warrant therapy administered with curative intent, ie, combined-modality therapy consisting of chemotherapy, surgery, and radiotherapy. Patients with ipsilateral supraclavicular metastases should be included in the stage IIIB category of the tumor-node-metastasis classification because their clinical course and prognosis are similar to those of patients with stage IIIB LABC.
Collapse
Affiliation(s)
- R A Brito
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 2000; 89:2195-201. [PMID: 11147589 DOI: 10.1002/1097-0142(20001201)89:11<2195::aid-cncr7>3.0.co;2-w] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND The authors conducted a single institution Phase II clinical trial to determine whether paclitaxel had antitumor activity in patients with metastatic breast carcinoma that was refractory to standard chemotherapy. METHODS Patients with metastatic breast carcinoma were eligible for the study if they had disease progression after at least 2 prior chemotherapy regimens. Patients who had received three prior regimens were treated in a separate cohort. All patients were required to have received doxorubicin in the past and were not eligible if they had received prior therapy with paclitaxel. The starting dose of paclitaxel for low risk patients was 175 mg/m2, administered as a 24-hour continuous infusion; the starting dose of paclitaxel was 150 mg/m2 for patients who had received > or = 3 prior regimens. Therapy was given every 3 weeks and continued for at least 2 courses unless there was evidence of rapidly progressing disease, for at least 3 courses if there was no change in disease and Grade 3 or 4 (based on National Cancer Institute toxicity criteria) toxicity was not noted, and for 6 courses beyond the maximum response in patients who demonstrated complete or partial responses and showed no evidence of disease progression. RESULTS Sixty-eight of 69 patients entered in the study were evaluable for response: 35 patients who had received 2 prior chemotherapy regimens for Stage IV disease and 33 patients who had received > or =3 prior regimens. A partial response was observed in 7 patients who had received 2 prior regimens, for an objective response rate of 20% (95% confidence interval [95% CI], 14-26%). In the group who had received > or = 3 prior regimens, a total of 6 partial responses were observed, for an objective response rate of 18% (95% CI, 12-23%). The median response duration was 8.2 months (range, 2.7-10.1 months) for the group who had received 2 prior regimens and 5.8 months (range, 2.1-9.5 months) for patients who received > or = 3 prior regimens. Responses were noted in patients with anthracycline-resistant tumors. CONCLUSIONS Paclitaxel was active in heavily pretreated patients with metastatic breast carcinoma, including anthracycline-resistant breast carcinoma.
Collapse
Affiliation(s)
- E Rivera
- Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4009, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Ibrahim NK, Buzdar AU, Asmar L, Theriault RL, Hortobagyi GN. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol 2000; 11:1597-601. [PMID: 11205469 DOI: 10.1023/a:1008315312795] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The purpose of this study was to evaluate the clinical outcome of doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients and to compare results in elderly patients with those in younger patients. PATIENTS AND METHODS We retrospectively reviewed the records of all patients aged 50 years or older treated in trials of doxorubicin-based adjuvant chemotherapy between 1974 and 1988. Old age was not an exclusion criterion for these trials. Patient characteristics, hematologic and nonhematologic side effects, patterns of recurrence, and causes of death were determined for patients aged 50-64 years and for patients aged 65 years or older, and results were compared between these two groups. Kaplan-Meier survival curves were plotted, and tested by the generalized Wilcoxon test. RESULTS A total of 390 patients aged 50 years or older were treated with doxorubicin-based adjuvant chemotherapy during the study period. Of these, 325 were aged 50-64 years (group 1), and 65 were aged 65 years or older (group 2). The median follow-up period for group 1 was 185 months (range 29-272+ months), and the median follow-up period for group 2 was 169 months (range 128-240+ months). There were no statistically significant differences between the two groups with respect to performance status, hormone receptor profile, tumor size, nodal status, or type of locoregional therapy. There also were no statistically significant differences between the two groups in recurrence patterns, disease-free survival, or overall survival. The granulocyte and platelet nadirs of cycles 1, 3, and 6 were similar between the two groups. No cumulative hematologic side effects were seen in either group. The occurrence of second malignancies was extremely low in both groups. In both groups, the majority of deaths were due to progression of disease. CONCLUSIONS Adjuvant doxorubicin-based chemotherapy is well tolerated in elderly breast cancer patients who have good performance status and normal cardiac ejection fraction. Adjuvant doxorubicin-based chemotherapy in these patients results in disease-free and overall survival rates similar to those seen in younger patients.
Collapse
Affiliation(s)
- N K Ibrahim
- Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
| | | | | | | | | |
Collapse
|